Recent Posts
- DiogenX raises €27.5M Series A financing to advance its first-in-class regenerative treatment for type 1 diabetes towards clinical development
- ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1)
- French biotech Calida Therapeutics launches with seed funding, leveraging US academic research in thrombo-inflammatory disorders
- AdBio partners appoints Geoffroy de Ribains as Managing Partner
- Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease